Categories: News

Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2020 Financial Results and Recent Operational Highlights

WATERTOWN, Mass., March 04, 2021 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that that it plans to host a conference call on Thursday, March 11, 2020, at 8:30 a.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2020, and recent operational highlights.

Individuals may participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and using confirmation code 10147796. Investors and the public can access the live and archived webcast of this call via the Investors & Media section of the company’s website, www.selectabio.com.

About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. The company’s first program aimed at addressing immunogenicity to AAV gene therapies is expected to enter clinical trials in early 2021 in partnership with AskBio for the treatment of methylmalonic acidemia (MMA), a rare metabolic disorder. A wholly-owned program focused on addressing IgA nephropathy driven by ImmTOR and a therapeutic enzyme is also in development among additional product candidates. Selecta recently licensed its Phase 3 clinical product candidate, SEL-212, in chronic refractory gout to Sobi. For more information, please visit www.selectabio.com.

For Investors:
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com

For Media:
Meredith Sosulski, Ph.D.
LifeSci Communications, LLC
+1-929-469-3851
msosulski@lifescicomms.com

Staff

Recent Posts

HealthArc Joins athenahealth’s Marketplace Program to Streamline Remote Care, Patient Outcomes, and Billing Process

HealthArc's unified remote care management platform integrates with athenahealth'sEHR to automate clinical documentation, enhance patient…

9 hours ago

AI/ML Innovations Inc. Enters Market Awareness Agreement

VICTORIA, BC / ACCESSWIRE / November 27, 2024 / AI/ML Innovations Inc. ("AI/ML" or the…

9 hours ago

Theralase(R) Release’s 3Q2024 Financial Statements

TORONTO, ON / ACCESSWIRE / November 27, 2024 / Theralase® Technologies Inc. (" Theralase® "…

9 hours ago

Top NY Plastic Surgeon Dr. Rubinstein Chosen to Train New Advanced BOTOX(R) Cosmetic Technique for Platysma Bands After FDA Approval

Renowned expert Dr. Rubinstein to train practitioners on new BOTOX® technique for smoother neck contours…

12 hours ago

AAMA Installs Loxie Kistler, EdD, MS, BSN, RN, CMA (AAMA), CHUC, as 2024–2026 Secretary

GRAND RAPIDS, MI / ACCESSWIRE / November 27, 2024 / The American Association of Medical…

12 hours ago